Global Leptospirosis Market, By Treatment (Medication, Others), Diagnosis (Complete Blood Count (CBC) Creatine Kinase, Liver Enzymes, Urinalysis, Blood Cultures), Symptoms (Headache, Muscle Ache, Jaundice, Vomiting, Diarrhea, Skin Rash, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the leptospirosis market is anticipated to grow rapidly during the forecast period. Leptospirosis is the most frequent zoonosis in the world, and it's linked to filthy environments and agricultural occupations that require contact with animals or water. Adventure travel and mud run sports or races involving fresh water or dirt exposure are increasing the risk for humans. Humans are not often thought of as reservoirs, yet they can shed leptospires on a regular basis and operate as reservoirs in locations where endemicity is high and waste sanitation is inadequate. In the United States, 100 to 150 infections are reported each year, with the majority occurring in the late summer and early fall. Many infections are undetected because moderate leptospirosis usually causes nonspecific, flu-like symptoms that go away on their own.
Data Bridge Market Research analyses that the leptospirosis market was valued at USD 447.8 million in 2021 and is expected to reach USD 708.36 million by 2029, registering a CAGR of 5.90% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Leptospirosis is a bacterial infection transferred by the Leptospira bacteria. The bacterium can be found in the kidneys of numerous mammals. It spreads to humans through breaks in the skin, such as cuts, open wounds, or dry areas, when contaminated animal poo material is present in the soil and water. It spreads through the nose, mouth, and genitals, but it's difficult to contract it from another person, however it can be transmitted through personal contact or nursing.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication, Others), Diagnosis (Complete Blood Count (CBC) Creatine Kinase, Liver Enzymes, Urinalysis, Blood Cultures), Symptoms (Headache, Muscle Ache, Jaundice, Vomiting, Diarrhea, Skin Rash, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Fresenius Kabi AG (Germany), Tolmar Pharmaceuticals, Inc. (US), Almirall, S.A (Spain), Baxter (US), Hikma Pharmaceuticals PLC (UK)
|
|
Market Opportunities
|
|
Leptospirosis Market Dynamics
Drivers
- Increasing prevalence of animal-related bacterial infections globally
The rising prevalence of animal-related bacterial infections globally is estimated to enhance the leptospirosis market's growth rate. Rats, skunks, opossums, foxes, and raccoons are among the animals that can spread the disease to humans. Open wounds, eyes, and mucous membranes are all areas where germs can enter the body.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of leptospirosis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing awareness about prevention and possible complications
The surging awareness about prevention and possible complications among people is estimated to enhance the market's expansion during the forecast period of 2022-2029. Jarisch-Herxheimer reaction when penicillin is given, severe bleeding and meningitis are the possible complications associated with this disease.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the leptospirosis market. Additionally, changing lifestyle of people and rising geriatric population will result in the expansion of leptospirosis market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the leptospirosis market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. The advent of new as well as more efficient diabetic treatment and monitoring products is estimated to boost the market’s growth rate in future.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the leptospirosis market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the leptospirosis market. Additionally, the scarcity of clinical suspicion and barriers to diagnostic capacity and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This leptospirosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the leptospirosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Leptospirosis is more common in tropical climates. As per the World Health Organization (WHO) it affects approximately 10 or more persons per 100,000 each year. It affects between 0.1 and 1 per 100,000 people in temperate climates. It can affect 100 or more persons per 100,000 in an outbreak.
Leptospirosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Leptospirosis Market
Over the projected period, the leptospirosis market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The leptospirosis market has also been hampered by the supply chain slowness.
Global Leptospirosis Market Scope
The leptospirosis market is segmented on the basis of treatment, diagnosis, symptoms, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
Antibiotics
- Ampicillin
- Azithromycin
- Ceftriaxone
- Doxycycline
- Penicillin
- Others
Others
Diagnosis
- Complete Blood Count (CBC)
- Creatine Kinase
- Liver Enzymes
- Urinalysis
- Blood Cultures
Symptoms
- Headache
- Muscle Ache
- Jaundice
- Vomiting
- Diarrhea
- Skin Rash
- Others
Dosage form
- Tablets
- Capsules
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Leptospirosis Market Regional Analysis/Insights
The leptospirosis market is analysed and market size insights and trends are provided by country, treatment, diagnosis symptoms, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Leptospirosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the leptospirosis market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing adoption of advanced technology will further influence the market’s growth rate in this region
Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and increasing animal husbandry and poultry in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Leptospirosis Market Share Analysis
The Leptospirosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to leptospirosis market.
Some of the major players operating in the leptospirosis market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Fresenius Kabi AG (Germany)
- Tolmar Pharmaceuticals, Inc. (US)
- Almirall, S.A (Spain)
- Baxter (US)
SKU-